Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dong-Jing Fu

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 13, 2023
Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)Carol Jamieson, Carla M Canuso, Dawn F Ionescu, et al.
Pharmacogenetics and Genomics|November 16, 2016
Genome-wide association study of paliperidone efficacyQingqin Li, Nathan E Wineinger, Dong-Jing Fu, et al.
Current Medical Research and Opinion|January 12, 2016
Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychoticsYongling Xiao, Erik Muser, Dong-Jing Fu, et al.
The Journal of Clinical Psychiatry|January 7, 2015
Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorderDong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.
Neuropsychiatric Disease and Treatment|January 1, 2024
A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical AntipsychoticsLien Wang, Xiaowei Chen, Xiaojing Gu, et al.
Brain and Behavior|July 21, 2023
Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder aloneDavid M Kern, Carla M Canuso, Ella Daly, et al.
BMC Psychiatry|August 11, 2023
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidalityDong-Jing Fu, Qiaoyi Zhang, Ling Shi, et al.
Journal of Clinical Psychopharmacology|August 19, 2021
Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or BehaviorCarla M Canuso, Dawn F Ionescu, Xiang Li, et al.
Schizophrenia Bulletin|February 9, 2018
Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia DiagnosesAriana E Anderson, Stephen Marder, Steven P Reise, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|March 9, 2025
Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled StudyColette Kosik-Gonzalez, Dong-Jing Fu, Li Nancy Chen, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 13, 2023
Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)Carol Jamieson, Carla M Canuso, Dawn F Ionescu, et al.
Pharmacogenetics and Genomics|November 16, 2016
Genome-wide association study of paliperidone efficacyQingqin Li, Nathan E Wineinger, Dong-Jing Fu, et al.
Current Medical Research and Opinion|January 12, 2016
Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychoticsYongling Xiao, Erik Muser, Dong-Jing Fu, et al.
The Journal of Clinical Psychiatry|January 7, 2015
Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorderDong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.
Neuropsychiatric Disease and Treatment|January 1, 2024
A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical AntipsychoticsLien Wang, Xiaowei Chen, Xiaojing Gu, et al.
Brain and Behavior|July 21, 2023
Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder aloneDavid M Kern, Carla M Canuso, Ella Daly, et al.
BMC Psychiatry|August 11, 2023
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidalityDong-Jing Fu, Qiaoyi Zhang, Ling Shi, et al.
Journal of Clinical Psychopharmacology|August 19, 2021
Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or BehaviorCarla M Canuso, Dawn F Ionescu, Xiang Li, et al.
Schizophrenia Bulletin|February 9, 2018
Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia DiagnosesAriana E Anderson, Stephen Marder, Steven P Reise, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|March 9, 2025
Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled StudyColette Kosik-Gonzalez, Dong-Jing Fu, Li Nancy Chen, et al.
Pageof 8